ROIV Roivant Sciences Ltd.
$34.41 +0.64%
Updated
Healthcare · Pharmaceutical Preparations
Roivant Sciences Ltd. (ROIV) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $24.9 billion. Shares last traded at $34.41, 11.8% below their 52-week high. Over the past year the stock is up 173.4%. Revenue declined 71.6% year over year.
Market Cap
$24.9B
Shares Out
722.3M
EPS (TTM)
$-1.96
P/E Ratio
—
P/S Ratio
3300.42
P/B Ratio
5.88
Dividend / Share
—
Dividend Yield
—
52-Week High
$39.00
52-Week Low
$12.54
Volume
231,959
Avg Vol (3m)
344,044.857
Performance
1W
-8.41%
1M
-0.48%
3M
+16.58%
6M
+15.72%
YTD
+56.97%
1Y
+173.35%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
43.22
SMA (50)
$35.26
SMA (200)
$28.42
Price vs SMA50
-2.40%
Price vs SMA200
+21.11%
ATR (14)
$1.60
Financials
Revenue
$8M
Net Income
$-266M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-6.3%
Return on Assets
-5.0%
Current Ratio
16.72
Debt / Equity
0.07
Revenue Growth (YoY)
-71.6%
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $-0.26 | 2026-08-06 |
| FY 2025 | $-0.54 | 2026-05-20 |
| Q3 2025 | $-0.88 | 2026-02-06 |
| Q2 2025 | $-0.49 | 2025-11-10 |
| Q1 2026 | $-0.33 | 2026-08-06 |
| FY 2025 | $-0.24 | 2026-05-20 |
Pharmaceutical Preparations peers
ROIV vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
P/S vs peers
3300.42 / 11.11 med
+29612% premium
1–14 of 14
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.